Related Experiment Videos
The MAL gene is expressed in primary mediastinal large B-cell lymphoma
C Copie-Bergman1, P Gaulard, L Maouche-Chrétien
1Département de Pathologie and EA 2348, the Service d'Hématologie Clinique, AP-HP, Hôpital Henri Mondor, Créteil, France.
Abstract:
Primary mediastinal large B-cell lymphoma (PMBL) appears to be a distinct clinicopathologic entity among diffuse large B-cell lymphomas (DLBLs). To find molecular alterations associated with this disease, we compared the mRNAs expressed in 3 PMBLs and 3 peripheral DLBLs by differential display-reverse transcription (DDRT) and identified a mRNA specifically expressed in PMBLs. Sequence analysis showed that this mRNA is encoded by the MAL gene, the expression of which was shown to be restricted to the T-cell lineage during hematopoiesis. MAL gene expression was demonstrated by Northern blot and reverse transcription-polymerase chain reaction (RT-PCR) in 8 of 12 PMBLs. However, there was little or no MAL gene expression in 8 peripheral DLBLs. Immunohistochemical analysis evidenced expression of MAL protein in tumoral B cells restricted to the PMBL subtype. Finally, Southern blot studies did not demonstrate rearrangement of the MAL gene. Altogether, our results indicate that MAL expression is recurrent in PMBLs, providing further evidence that PMBL represents a distinct entity among DLBLs. Because MAL protein is located in detergent-insoluble glycolipid-enriched membrane (GEM) domains involved in lymphocyte signal transduction, abnormal expression of MAL protein in the B-lymphoid lineage may have significant implications in PMBL lymphomagenesis.
Insights
Primary mediastinal large B-cell lymphoma (PMBL) shows distinct molecular features. Researchers found the MAL gene is specifically expressed in PMBL, suggesting it is a unique lymphoma subtype.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- Primary mediastinal large B-cell lymphoma (PMBL) is a distinct subtype of diffuse large B-cell lymphoma (DLBL).
- Understanding the molecular basis of PMBL is crucial for its classification and potential targeted therapies.
Purpose of the Study:
- To identify molecular alterations that distinguish PMBL from other DLBL subtypes.
- To investigate the role of the MAL gene in PMBL pathogenesis.
Main Methods:
- Differential display-reverse transcription (DDRT) to compare mRNA expression between PMBL and peripheral DLBL.
- Northern blot, RT-PCR, and immunohistochemistry to confirm MAL gene and protein expression.
- Southern blot to assess MAL gene rearrangement.
Main Results:
- A specific mRNA, encoded by the MAL gene, was identified in PMBL but not in peripheral DLBL.
- MAL gene expression was detected in 8/12 PMBLs and minimally in peripheral DLBLs.
- MAL protein was expressed in tumoral B cells of PMBL, and the MAL gene showed no rearrangement.
Conclusions:
- Recurrent MAL gene expression in PMBL supports its classification as a distinct clinicopathologic entity.
- Abnormal MAL protein expression in B-lymphoid cells may play a role in PMBL lymphomagenesis.
- MAL protein's function in signal transduction pathways suggests implications for PMBL development.